FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002463981> ?p ?o ?g. }

• W2002463981 endingPage "208" @default.
• W2002463981 startingPage "196" @default.
• W2002463981 abstract "Inhaled corticosteroids are considered by many to be the anti-inflammatory therapy of choice in adult asthma, given their remarkable efficacy and apparent safety. They are presently being prescribed to more patients, at larger doses, and for longer periods of time than ever before. Oropharyngeal candidiasis and dysphonia are the most commonly recognized adverse effects of therapy, but these topical phenomena cause no significant morbidity and are easily managed. By contrast, there is now increasing concern about the potential systemic effects of inhaled corticosteroids. These putative effects may include adrenal suppression, bone loss, skin thinning, increased cataract formation, decreased linear growth in children, metabolic changes, and behavioral abnormalities. Changes in adrenal function have been noted in patients using medications such as beclomethasone dipropionate and budesonide in doses exceeding 1,500 μg/day. The clinical relevance of these changes has yet to be clarified. Several short-term and cross-sectional studies have also revealed changes in biochemical markers of bone turnover and retrospective studies have found reduced bone density in asthmatics treated regularly with inhaled steroids. Long-term prospective studies assessing bone density changes remain to be done. Although much controversy exists, there is no unequivocal evidence that conventional doses of inhaled steroids significantly retard bone growth in children. Reports on skin changes, increased cataract formation, and behavioral changes are difficult to interpret because of several confounding factors. Although inhaled steroids should, at the present time, continue to be a recommended therapeutic option to all patients with symptomatic asthma, they should always be used in the lowest dosage compatible with disease control. Inhaled corticosteroids are considered by many to be the anti-inflammatory therapy of choice in adult asthma, given their remarkable efficacy and apparent safety. They are presently being prescribed to more patients, at larger doses, and for longer periods of time than ever before. Oropharyngeal candidiasis and dysphonia are the most commonly recognized adverse effects of therapy, but these topical phenomena cause no significant morbidity and are easily managed. By contrast, there is now increasing concern about the potential systemic effects of inhaled corticosteroids. These putative effects may include adrenal suppression, bone loss, skin thinning, increased cataract formation, decreased linear growth in children, metabolic changes, and behavioral abnormalities. Changes in adrenal function have been noted in patients using medications such as beclomethasone dipropionate and budesonide in doses exceeding 1,500 μg/day. The clinical relevance of these changes has yet to be clarified. Several short-term and cross-sectional studies have also revealed changes in biochemical markers of bone turnover and retrospective studies have found reduced bone density in asthmatics treated regularly with inhaled steroids. Long-term prospective studies assessing bone density changes remain to be done. Although much controversy exists, there is no unequivocal evidence that conventional doses of inhaled steroids significantly retard bone growth in children. Reports on skin changes, increased cataract formation, and behavioral changes are difficult to interpret because of several confounding factors. Although inhaled steroids should, at the present time, continue to be a recommended therapeutic option to all patients with symptomatic asthma, they should always be used in the lowest dosage compatible with disease control." @default.
• W2002463981 created "2016-06-24" @default.
• W2002463981 creator A5021493691 @default.
• W2002463981 creator A5036017418 @default.
• W2002463981 creator A5090459826 @default.
• W2002463981 date "1995-02-01" @default.
• W2002463981 modified "2023-10-02" @default.
• W2002463981 title "Adverse effects of inhaled corticosteroids" @default.
• W2002463981 cites W179505558 @default.
• W2002463981 cites W1965433092 @default.
• W2002463981 cites W1966491055 @default.
• W2002463981 cites W1967827648 @default.
• W2002463981 cites W1968900414 @default.
• W2002463981 cites W1970038243 @default.
• W2002463981 cites W1972488771 @default.
• W2002463981 cites W1976445312 @default.
• W2002463981 cites W1977497452 @default.
• W2002463981 cites W1978702016 @default.
• W2002463981 cites W1979035516 @default.
• W2002463981 cites W1982314879 @default.
• W2002463981 cites W1984135011 @default.
• W2002463981 cites W1984723538 @default.
• W2002463981 cites W1985202939 @default.
• W2002463981 cites W1986034121 @default.
• W2002463981 cites W1986555896 @default.
• W2002463981 cites W1986764494 @default.
• W2002463981 cites W1990144985 @default.
• W2002463981 cites W1991545126 @default.
• W2002463981 cites W1991775872 @default.
• W2002463981 cites W1991903923 @default.
• W2002463981 cites W1992021741 @default.
• W2002463981 cites W1992170505 @default.
• W2002463981 cites W1992874758 @default.
• W2002463981 cites W1992952166 @default.
• W2002463981 cites W1994441935 @default.
• W2002463981 cites W1995567514 @default.
• W2002463981 cites W1996742516 @default.
• W2002463981 cites W1997177678 @default.
• W2002463981 cites W2001053301 @default.
• W2002463981 cites W2001320959 @default.
• W2002463981 cites W2001564937 @default.
• W2002463981 cites W2001618254 @default.
• W2002463981 cites W2001756867 @default.
• W2002463981 cites W2002104195 @default.
• W2002463981 cites W2003622677 @default.
• W2002463981 cites W2010976841 @default.
• W2002463981 cites W2013028382 @default.
• W2002463981 cites W2015654101 @default.
• W2002463981 cites W2016270114 @default.
• W2002463981 cites W2017321545 @default.
• W2002463981 cites W2018076401 @default.
• W2002463981 cites W2018937175 @default.
• W2002463981 cites W2019636120 @default.
• W2002463981 cites W2022082810 @default.
• W2002463981 cites W2023306095 @default.
• W2002463981 cites W2024663693 @default.
• W2002463981 cites W2025670657 @default.
• W2002463981 cites W2025853082 @default.
• W2002463981 cites W2026044056 @default.
• W2002463981 cites W2027210280 @default.
• W2002463981 cites W2027419778 @default.
• W2002463981 cites W2028184859 @default.
• W2002463981 cites W2030639081 @default.
• W2002463981 cites W2031111440 @default.
• W2002463981 cites W2031810689 @default.
• W2002463981 cites W2035211957 @default.
• W2002463981 cites W2036700807 @default.
• W2002463981 cites W2036902629 @default.
• W2002463981 cites W2041321156 @default.
• W2002463981 cites W2042457399 @default.
• W2002463981 cites W2044236864 @default.
• W2002463981 cites W2044796619 @default.
• W2002463981 cites W2045358685 @default.
• W2002463981 cites W2047448152 @default.
• W2002463981 cites W2047540788 @default.
• W2002463981 cites W2047716244 @default.
• W2002463981 cites W2048360493 @default.
• W2002463981 cites W2048570557 @default.
• W2002463981 cites W2051129763 @default.
• W2002463981 cites W2052273212 @default.
• W2002463981 cites W2052480651 @default.
• W2002463981 cites W2053127947 @default.
• W2002463981 cites W2053525434 @default.
• W2002463981 cites W2053945234 @default.
• W2002463981 cites W2054806186 @default.
• W2002463981 cites W2055030825 @default.
• W2002463981 cites W2057548406 @default.
• W2002463981 cites W2060279005 @default.
• W2002463981 cites W2060389898 @default.
• W2002463981 cites W2065389845 @default.
• W2002463981 cites W2066830667 @default.
• W2002463981 cites W2068611987 @default.
• W2002463981 cites W2069081942 @default.
• W2002463981 cites W2069849198 @default.
• W2002463981 cites W2070885819 @default.
• W2002463981 cites W2075129738 @default.
• W2002463981 cites W2076863034 @default.
• W2002463981 cites W2077234426 @default.

• next